Bausch Health Companies Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名71/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價7.29。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Bausch Health Companies Inc評分
相關信息
行業排名
71 / 158
全市場排名
176 / 4563
所屬行業
藥品
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
持有
評級
7.286
目標均價
+6.83%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Bausch Health Companies Inc亮點
亮點風險
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
公司代碼BHC
公司Bausch Health Companies Inc
CEOAppio (Thomas J)
網址https://www.bauschhealth.com/
常見問題
Bausch Health Companies Inc(BHC)的當前股價是多少?
Bausch Health Companies Inc(BHC)的當前股價是 7.195。
Bausch Health Companies Inc 的股票代碼是什麼?
Bausch Health Companies Inc的股票代碼是BHC。
Bausch Health Companies Inc股票的52週最高點是多少?
Bausch Health Companies Inc股票的52週最高點是11.970。
Bausch Health Companies Inc股票的52週最低點是多少?
Bausch Health Companies Inc股票的52週最低點是5.910。
Bausch Health Companies Inc的市值是多少?
Bausch Health Companies Inc的市值是2.67B。
Bausch Health Companies Inc的淨利潤是多少?
Bausch Health Companies Inc的淨利潤為-46.00M。
現在Bausch Health Companies Inc(BHC)的股票是買入、持有還是賣出?
根據分析師評級,Bausch Health Companies Inc(BHC)的總體評級為持有,目標價格為7.286。
Bausch Health Companies Inc(BHC)股票的每股收益(EPS TTM)是多少
Bausch Health Companies Inc(BHC)股票的每股收益(EPS TTM)是0.979。